Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020062251 - COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF

Publication Number WO/2020/062251
Publication Date 02.04.2020
International Application No. PCT/CN2018/109115
International Filing Date 30.09.2018
IPC
C07D 217/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
217Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
24Oxygen atoms
A61K 31/4725 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
CPC
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Applicants
  • XW LABORATORIES, INC. [CN]/[CN] (CN)
  • XW LABORATORIES INC. [GB]/[GB]
Inventors
  • XIANG, Jia-Ning
  • XU, Xuesong
  • FENG, Yi
  • ENG, Wai-Si
Agents
  • TSINGYIHUA INTELLECTUAL PROPERTY LLC
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
(FR) COMPOSÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR 3 DE L'HISTAMINE NEURONALE ET LEURS UTILISATIONS
Abstract
(EN)
The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
(FR)
La présente invention concerne des composés de formule (A) en tant qu'antagonistes de H3R, ainsi que leur préparation et leurs utilisations, et des compositions pharmaceutiques comprenant ces composés et leurs utilisations en tant que modulateurs des fonctions du récepteur de l'histamine 3 (H3R). La présente invention concerne également les utilisations des composés ou des compositions pharmaceutiques dans le traitement ou la prévention de certains troubles et maladies en rapport avec les fonctions de H3R chez l'homme.
Latest bibliographic data on file with the International Bureau